URGN - UroGen Pharma Ltd. Ordinary Shares -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies.
IPO Date: May 4, 2017
Sector: Healthcare
Industry: Biotech
Market Cap: $2.11B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.66 | 3.18%
Avg Daily Range (30 D): $1.06 | 2.29%
Avg Daily Range (90 D): $1.02 | 2.68%
Institutional Daily Volume
Avg Daily Volume: .34M
Avg Daily Volume (30 D): .68M
Avg Daily Volume (90 D): .63M
Trade Size
Avg Trade Size (Sh.): 85
Avg Trade Size (Sh.) (30 D): 61
Avg Trade Size (Sh.) (90 D): 60
Institutional Trades
Total Institutional Trades: 1,045
Avg Institutional Trade: $1.92M
Avg Institutional Trade (30 D): $3.59M
Avg Institutional Trade (90 D): $2.7M
Avg Institutional Trade Volume: .1M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.09M
Avg Closing Trade (30 D): $4.83M
Avg Closing Trade (90 D): $4.02M
Avg Closing Volume: 103.08K
 
News
Sep 8, 2026 @ 12:33 PM
Take the Zacks Approach to Beat the Markets: Oport...
Source: Zacks.Com
Sep 4, 2026 @ 12:00 PM
UroGen Pharma Announces Inducement Grants Under Na...
Source: Na
Jul 12, 2026 @ 6:11 PM
UroGen's Chief Medical Officer Sold $400,000 in St...
Source: Jonathan Ponciano
Jun 14, 2026 @ 3:14 PM
Is UroGen Pharma a Stock to Sell After Its Chief M...
Source: Cory Renauer
Mar 13, 2026 @ 12:00 PM
UroGen Applauds BCAN’s New Faces of Bladder...
Source: Urogen Pharma Ltd.
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-1.97 $-.28 $-.47
Diluted EPS
Revenue $188.73M $72.46M $50.96M
Gross Profit $171.46M $65.88M $46.82M
Net Income / Loss $-97.64M $-14.35M $-23.57M
Operating Income / Loss $-66.65M $.11M $-20.26M
Cost of Revenue $17.28M $6.57M $4.14M
Net Cash Flow $-13.53M $-30.83M $-.8M
PE Ratio